Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Enrollment will begin in January 2026Participants will be treated with buntanetap for 36 monthsThe study aims to enroll 500 ...
Fierce Pharma

Pfizer confirms patient death in Hympavzi hemophilia extension study

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
MedPage Today on MSN

Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression

A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...
TipRanks on MSN

Pacira ends hip osteoarthritis injection study for ZILRETTA: What investors should know

Pacira ($PCRX) announced an update on their ongoing clinical study. Study Overview: Pacira Pharmaceuticals is running a Phase 2 trial titled “A ...
Seeking Alpha

Cassava Sciences: Open Label Study Data Unconvincing But Indicative Of Good Things

Cassava Sciences' phase 2 data was from a nonrandomized trial, therefore unconvincing. However, it indicated drug efficacy quite strongly. Phase 3 trial data will be major catalysts. Cassava Sciences ...
TipRanks on MSN

Ascentage Pharma advances olverembatinib with new liver function study, offering gradual upside for investors

Ascentage Pharma Group International ($HK:6855) announced an update on their ongoing clinical study. Study Overview The trial, officially titled ...
Seeking Alpha

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Atai Beckley BPL-003 phase IIb open-label extension ...
Business Wire

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

CHICAGO--(BUSINESS WIRE)--An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of ...
ascopubs.org

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive ...

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. This is an ASCO Meeting ...
ascopubs.org

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer ...